BPC-157 is NOT suitable for individuals with: Active cancer (as it promotes new blood vessel growth)
The result: Increased lipolysis : Fat cells release stored fatty acids for use as fuel Inhibited lipogenesis : Dietary fats are less readily converted to stored body fat No significant IGF-1 stimulation : Means no growth of existing tumors or cancer risk amplification that concerns some clinicians with full GH No significant glucose disruption : Unlike full HGH, which causes insulin resistance at therapeutic doses, AOD-9604 shows minimal glucose impact in studies This makes it uniquely well-suited for fat loss use cases where full HGH would be too blunt an instrument
While effective for some, these approaches often fall short for individuals with underlying metabolic challenges, hormonal imbalances, or age-related barriers
For more insights, explore our health & peptide blog or return to the Peptides Unleashed homepage to grab free ebook on Power of Peptides
That doc closed his practice which is when I found you
Clinical trials involving over 900 participants showed AOD-9604 to be well-tolerated with side effects indistinguishable from placebo in most studies
